Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. NOXOF.PINK

Noxopharm Limited (NOXOF PINK) stock market data APIs

$0.045 0(0%) as of July 25, 2024
Price chart is built with Anychart

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Noxopharm Limited Financial Data Overview

0.045
0.045
-
0.045
0.045
0.03-0.045
13 449 K
292 M
3 876 K
0.77
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NOXOF',
Type: 'Common Stock',
Name: 'Noxopharm Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00R83PYB1',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'June',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Noxopharm Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 876 K
  • EBITDA -7 272 196
  • Earnings Per Share -0.03
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Noxopharm Limited Earnings via APIs

  • Latest Release 2024-07-22
  • EPS/Forecast NaN

Get Noxopharm Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Noxopharm Limited latest news via APIs

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with...
  • FREE CASH FLOW

Will Noxopharm (ASX:NOX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recur...
  • FREE CASH FLOW
  • REVENUE GROWTH
Do you have any questions?
support@eodhistoricaldata.com